(Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Jan, 2025 |
Sales | 2,240 | 23,900 | 60,880 | 0 | 0 |
Sales Growth | -90.63% | -60.74% | unch | unch | unch |
Net Income | -42,190 | -18,740 | -17,140 | -10 | 0 |
Net Income Growth | -125.13% | -9.33% | -171,317.13% | unch | unch |
Sab Biotherapeutics Inc WT (SABSW)
Sab Biotherapeutics Inc WT (SABSW)
0.1474 +0.0674 (+84.25%) 01/16/25 [NASDAQ]
0.0041 x 120,000 0.1474 x 300
Realtime by (Cboe BZX)
0.0041 x 120,000 0.1474 x 300
Realtime - - (-) -
for Thu, Jan 16th, 2025
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.
Fiscal Year End Date: 12/31